Research Objectives

Discover the forefront of our scientific inquiry as we target biospecimen samples to drive breakthroughs and innovations.

Three Major Research Areas

1. Stable Biospecimen Collection and Storage:

  • Significance:

The stability, quality, and integrity of biospecimens are fundamental to the accuracy and reliability of biomedical research findings [1]. By enhancing the stability and affordability in biospecimen processing, preservation, and distribution, we can significantly accelerate the pace of medical discoveries and clinical translations. Efficient biospecimen management directly translates to more accurate diagnostics, better understanding of diseases, and the faster development of therapeutic solutions [2].

  • Recent Research Findings:

Recent advancements in the field have highlighted the potential of innovative preservation technologies like cryopreservation [3], lyophilization [4], and the utilization of preservative chemicals to extend the stability and usability of biospecimens. Moreover, automated processing and blockchain technology have emerged as promising solutions to enhance the traceability and cost-effectiveness of biospecimen distribution [5].

  • Greenfield’s Unique Position:

Greenfield Bio, with its expansive biospecimen sample repository and a team of dedicated scientists, is uniquely positioned to pioneer advancements in this domain. Our extensive repository provides a diverse and rich source of biospecimens that facilitates in-depth research and validation of novel preservation and processing methodologies. Additionally, our scientists, with their expertise in biopreservation, molecular biology, and supply chain management, are driving the innovation to establish standardized, economical, and reliable biospecimen handling protocols.

2. Immune Profiling for Disease States:

  • Significance:

Immune profiling provides invaluable insights into the intricate interactions between the immune system and various diseases [6]. This knowledge is instrumental in developing targeted therapeutic and prophylactic interventions. Particularly in the era of personalized medicine, understanding the heterogeneity of immune responses across different populations is fundamental [7].

  • Recent Research Findings:

Advances in high-throughput sequencing and computational biology have facilitated deeper understanding of the immune landscape across various diseases and populations [8]. Recent studies have elucidated key immune signatures associated with aging [9], autoimmune disorders, and infectious diseases among diverse demographic groups.

  • Greenfield’s Unique Position:

With a treasure trove of biospecimen samples representing a wide array of populations and disease states, Greenfield Bio is well-poised to contribute significantly to the field of immune profiling. Our seasoned immunologists and computational biologists are adept at harnessing cutting-edge technologies to dissect the complex immune responses and delineate disease-associated immune signatures. Our endeavors will likely yield crucial data that could inform the development of novel diagnostic tools and personalized therapeutic strategies.

3. Longitudinal Variations in Multiomics

  • Significance:

Unveiling longitudinal variations in multiomics holds the promise of revolutionizing our understanding of health and disease evolution [10]. It opens the avenue to predictive modeling of disease trajectories, enabling early interventions and personalized healthcare strategies.

  • Recent Research Findings:

Emerging research has begun to elucidate the dynamic multiomic alterations in response to environmental exposures, lifestyle changes, and disease progression [11]. These findings are paving the way for the development of models that can predict health and disease outcomes over time [12].

  • Greenfield’s Unique Position:

Greenfield Bio, with its rich biospecimen repository and multi-disciplinary team of experts, stands at the vanguard of investigating longitudinal multiomics variations. Our longitudinal sample collections, coupled with advanced analytical capabilities, allow for in-depth exploration of multiomic dynamics over time. By leveraging our robust infrastructure and scientific expertise, we are committed to advancing the frontier of predictive health and precision medicine, making significant strides towards a more proactive and personalized healthcare paradigm.

Bibliography

[1]       M.-D. Servais et al., “Addressing the quality challenge of a human biospecimen biobank through the creation of a quality management system,” PLOS ONE, vol. 17, no. 12, p. e0278780, Dec. 2022, doi: 10.1371/journal.pone.0278780.

[2]       S. Y. Nussbeck, D. Skrowny, S. O’Donoghue, T. G. Schulze, and K. Helbing, “How to Design Biospecimen Identifiers and Integrate Relevant Functionalities into Your Biospecimen Management System,” Biopreservation Biobanking, vol. 12, no. 3, pp. 199–205, Jun. 2014, doi: 10.1089/bio.2013.0085.

[3]       M. Amini and J. D. Benson, “Technologies for Vitrification Based Cryopreservation,” Bioengineering, vol. 10, no. 5, p. 508, Apr. 2023, doi: 10.3390/bioengineering10050508.

[4]       A. Molnar et al., “Lyophilization and homogenization of biological samples improves reproducibility and reduces standard deviation in molecular biology techniques,” Amino Acids, vol. 53, no. 6, pp. 917–928, 2021, doi: 10.1007/s00726-021-02994-w.

[5]       M. I. Ortiz-Lizcano, E. Arias-Antunez, Á. Hernández Bravo, M. B. Caminero, T. Rojo Guillen, and S. H. Nam Cha, “Increasing the security and traceability of biological samples in biobanks by blockchain technology,” Comput. Methods Programs Biomed., vol. 231, p. 107379, Apr. 2023, doi: 10.1016/j.cmpb.2023.107379.

[6]       S. Chuah and V. Chew, “High-dimensional immune-profiling in cancer: implications for immunotherapy,” J. Immunother. Cancer, vol. 8, no. 1, p. e000363, Feb. 2020, doi: 10.1136/jitc-2019-000363.

[7]       R. Satija and A. K. Shalek, “Heterogeneity in immune responses: from populations to single cells,” Trends Immunol., vol. 35, no. 5, pp. 219–229, May 2014, doi: 10.1016/j.it.2014.03.004.

[8]       E. Papalexi and R. Satija, “Single-cell RNA sequencing to explore immune cell heterogeneity,” Nat. Rev. Immunol., vol. 18, no. 1, Art. no. 1, Jan. 2018, doi: 10.1038/nri.2017.76.

[9]       C. Franceschi, S. Salvioli, P. Garagnani, M. de Eguileor, D. Monti, and M. Capri, “Immunobiography and the Heterogeneity of Immune Responses in the Elderly: A Focus on Inflammaging and Trained Immunity,” Front. Immunol., vol. 8, 2017, Accessed: Oct. 18, 2023. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2017.00982

[10]     W. Zhou et al., “Longitudinal multi-omics of host–microbe dynamics in prediabetes,” Nature, vol. 569, no. 7758, Art. no. 7758, May 2019, doi: 10.1038/s41586-019-1236-x.

[11]     M. R. Sailani et al., “Deep longitudinal multiomics profiling reveals two biological seasonal patterns in California,” Nat. Commun., vol. 11, no. 1, Art. no. 1, Oct. 2020, doi: 10.1038/s41467-020-18758-1.

[12]     M. Poyet et al., “A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research,” Nat. Med., vol. 25, no. 9, Art. no. 9, Sep. 2019, doi: 10.1038/s41591-019-0559-3.